Cargando…

PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses

The purpose of this study was to describe the use of PLDLA/TPU matrix enriched with cyclosporine A (CsA) as a therapeutic platform in horses with immune-mediated keratitis (IMMK) with an in vitro evaluation CsA release and degradation of the blend as well as determination of the safety and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Padjasek, Martyna, Cisło-Sankowska, Anna, Lis-Bartos, Anna, Qasem, Badr, Marycz, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057311/
https://www.ncbi.nlm.nih.gov/pubmed/36982806
http://dx.doi.org/10.3390/ijms24065735
_version_ 1785016331365515264
author Padjasek, Martyna
Cisło-Sankowska, Anna
Lis-Bartos, Anna
Qasem, Badr
Marycz, Krzysztof
author_facet Padjasek, Martyna
Cisło-Sankowska, Anna
Lis-Bartos, Anna
Qasem, Badr
Marycz, Krzysztof
author_sort Padjasek, Martyna
collection PubMed
description The purpose of this study was to describe the use of PLDLA/TPU matrix enriched with cyclosporine A (CsA) as a therapeutic platform in horses with immune-mediated keratitis (IMMK) with an in vitro evaluation CsA release and degradation of the blend as well as determination of the safety and efficacy of that platform used in the animal model. The kinetics of the CsA release from matrices constructed of thermoplastic polyurethane (TPU) polymer and a copolymer of L-lactide with DL-lactide (PLDLA) (80:20) in the TPU (10%) and a PLDL (90%) polymer blend were studied. Moreover, we used the STF (Simulated Tear Fluid) at 37 °C as a biological environment to assess the CsA release and its degradation. Additionally, the platform described above was injected subconjunctival in the dorsolateral quadrant of the globe after standing sedation of horses with diagnosed superficial and mid-stromal IMMK. The obtained results indicated that the CsA release rate in the fifth week of the study increased significantly by the value of 0.3% compared to previous weeks. In all of the cases, the TPU/PLA doped with 12 mg of the CsA platform effectively reduced the clinical symptoms of keratitis, leading to the complete remission of the corneal opacity and infiltration four weeks post-injection. The results from this study showed that the PLDLA/TPU matrix enriched with the CsA platform was well tolerated by the equine model and effective in treating superficial and mid-stromal IMMK.
format Online
Article
Text
id pubmed-10057311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100573112023-03-30 PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses Padjasek, Martyna Cisło-Sankowska, Anna Lis-Bartos, Anna Qasem, Badr Marycz, Krzysztof Int J Mol Sci Article The purpose of this study was to describe the use of PLDLA/TPU matrix enriched with cyclosporine A (CsA) as a therapeutic platform in horses with immune-mediated keratitis (IMMK) with an in vitro evaluation CsA release and degradation of the blend as well as determination of the safety and efficacy of that platform used in the animal model. The kinetics of the CsA release from matrices constructed of thermoplastic polyurethane (TPU) polymer and a copolymer of L-lactide with DL-lactide (PLDLA) (80:20) in the TPU (10%) and a PLDL (90%) polymer blend were studied. Moreover, we used the STF (Simulated Tear Fluid) at 37 °C as a biological environment to assess the CsA release and its degradation. Additionally, the platform described above was injected subconjunctival in the dorsolateral quadrant of the globe after standing sedation of horses with diagnosed superficial and mid-stromal IMMK. The obtained results indicated that the CsA release rate in the fifth week of the study increased significantly by the value of 0.3% compared to previous weeks. In all of the cases, the TPU/PLA doped with 12 mg of the CsA platform effectively reduced the clinical symptoms of keratitis, leading to the complete remission of the corneal opacity and infiltration four weeks post-injection. The results from this study showed that the PLDLA/TPU matrix enriched with the CsA platform was well tolerated by the equine model and effective in treating superficial and mid-stromal IMMK. MDPI 2023-03-17 /pmc/articles/PMC10057311/ /pubmed/36982806 http://dx.doi.org/10.3390/ijms24065735 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Padjasek, Martyna
Cisło-Sankowska, Anna
Lis-Bartos, Anna
Qasem, Badr
Marycz, Krzysztof
PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses
title PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses
title_full PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses
title_fullStr PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses
title_full_unstemmed PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses
title_short PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses
title_sort pldla/tpu matrix enriched with cyclosporine a as a therapeutic platform for immune-mediated keratitis (immk) in horses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057311/
https://www.ncbi.nlm.nih.gov/pubmed/36982806
http://dx.doi.org/10.3390/ijms24065735
work_keys_str_mv AT padjasekmartyna pldlatpumatrixenrichedwithcyclosporineaasatherapeuticplatformforimmunemediatedkeratitisimmkinhorses
AT cisłosankowskaanna pldlatpumatrixenrichedwithcyclosporineaasatherapeuticplatformforimmunemediatedkeratitisimmkinhorses
AT lisbartosanna pldlatpumatrixenrichedwithcyclosporineaasatherapeuticplatformforimmunemediatedkeratitisimmkinhorses
AT qasembadr pldlatpumatrixenrichedwithcyclosporineaasatherapeuticplatformforimmunemediatedkeratitisimmkinhorses
AT maryczkrzysztof pldlatpumatrixenrichedwithcyclosporineaasatherapeuticplatformforimmunemediatedkeratitisimmkinhorses